GlassScriptPhysician profile
Roberto Manllo-Karim
NPI 1891794616
$8,872.63
in general payments reported to CMS, 2019-2025
18 companies · $471 in 2025
The $471 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,955 · 2020: $42.98 · 2021: $204 · 2022: $611 · 2023: $411 · 2024: $177 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,035 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,034.74 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $6,824.83 | 2019-2025 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $338.19 | 2019-2025 | Velphoro, Korsuva, Velphoro |
| Akebia Therapeutics INC | $336.63 | 2019-2025 | Vafseo, Auryxia |
| Otsuka America Pharmaceutical, INC. | $275.33 | 2019-2025 | Jynarque, Voyxact |
| Horizon Therapeutics Plc | $195.93 | 2021-2022 | |
| Genzyme Corporation | $195.52 | 2019-2025 | |
| Glaxosmithkline, LLC. | $182.59 | 2022-2023 | Benlysta, Jesduvroq |
| Novo Nordisk INC | $139.48 | 2023-2025 | Ozempic |
| Amgen INC. | $106.65 | 2021-2025 | Tavneos, Krystexxa |
| Aurinia Pharma U.S., INC. | $71.94 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $64.95 | 2022-2024 | Acthar |
| Calliditas Therapeutics US INC. | $41.44 | 2022-2024 | |
| Gilead Sciences, INC. | $32.92 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.79 | 2022 | |
| Vifor Pharma, INC. | $19.94 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.50 | 2024 | Jardiance |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Manllo-Karim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.